Premium
Is QTc the Right Surrogate in Adequately Assessing the Risk for TdP for Development Compound Candidates? A Call to Investigate
Author(s) -
Krishna Rajesh
Publication year - 2021
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/jcph.1912
Subject(s) - qt interval , medicine , liability , drug development , ventricular tachycardia , proarrhythmia , intensive care medicine , business , risk analysis (engineering) , cardiology , pharmacology , finance , drug